Pharmaceutical Leader and Innovation Breakthrough: GRAND PHARMA (00512) Accelerates Value Realization in 2025.

Since 2026, the Hong Kong stock pharmaceutical sector has been constantly fluctuating due to multiple external factors. Unlike the bull market for innovative drugs in 2025, which was mainly driven by expectations for a single innovative target and pipeline BD, investors in the current Hong Kong stock pharmaceutical sector are more willing to pay a premium for clear value realization. "Accelerated innovation-globalization realization-valuation enhancement" has gradually become the key logic for researching the "investment certainty" of innovative drug companies. Against this market background, GRAND PHARMA (00512) has guided its strategy with "globalized operational layout and dual-cycle operation development". By leveraging its global institutional advantages formed by its innovative research and development, diverse pipeline, and commercialization promotion, GRAND PHARMA steadily realizes its global commercial achievements. Its demonstrated counter-cyclical growth momentum and development resilience align with the investment sentiment in the secondary market and have become the starting point for investors to analyze GRAND PHARMA's newly released 2025 annual performance. It was revealed that on March 26, GRAND PHARMA announced its 2025 annual performance. The announcement showed that in 2025, the company recorded revenue of approximately 12.28 billion Hong Kong dollars, with a growth of about 15% over the previous year when excluding the impact of centralized procurement. During the period, after adjusting the impact of Telix's investment fair value change on the company's profit, the company's adjusted operating net profit attributable to owners was approximately 1.49 billion Hong Kong dollars. The temporary impact of centralized procurement price reductions has been adequately cleared, and thanks to the continuous realization of technological innovation achievements, GRAND PHARMA has maintained high-quality development with strong resilience. Based on robust performance, the company plans to maintain high dividends and intends to distribute approximately 600 million Hong Kong dollars in dividends, reflecting the company's good profitability realization ability and shareholder return awareness, as well as conveying confidence in long-term development to the market. The anti-tumor business of nuclear medicine has experienced significant growth, leading the global industry chain layout Looking back at 2025, the growth trajectory of GRAND PHARMA is clear and powerful: as an innovative pharmaceutical company with strategic vision and long-term layout, the company continues to consolidate its industry-leading position by leading in core business, rich product matrix layout, and incubating internal growth-driven power, injecting strong momentum into long-term growth. In this process, the rapid growth of the nuclear medicine sector and the key breakthrough of STC3141, the world's first innovative drug, as well as the synergistic efforts of multiple business sectors, have already opened the door for GRAND PHARMA's value transformat...